Trubion Finds Kindred Spirit in Facet For Co-Development And Commercialization
This article was originally published in The Pink Sheet Daily
Executive Summary
Recently launched spinout from PDL BioPharma pays $20 million upfront to Trubion for chronic lymphocytic leukemia candidate.
You may also be interested in...
Emergent BioSolutions Takes Out Troubled Trubion For $97 Million
Known for its biodefense work, Emergent used cash from its anthrax vaccine contracts to scoop up a developer of antibody-like therapies for autoimmune and cancer indications.
Emergent BioSolutions Takes Out Troubled Trubion For $97 Million
Known for its biodefense work, Emergent used cash from its anthrax vaccine contracts to scoop up a developer of antibody-like therapies for autoimmune and cancer indications.
Facet Cuts Shareholder Deals To Fight Off Hostile Biogen Bid
Biogen Idec will drop its $450 million tender offer, but the companies still must work together to develop two key drugs.